实施指导方针导向的医学治疗和心力衰竭的因素,减少射分数
Firaol Wassie Bekele1, Wubshet Abraham Alemu2, Koricho Simie Tolla1
1Department of Internal Medicine, College of Health Sciences, Arsi University, Asella, Ethiopia.
BMC cardiovascular disorders
|October 9, 2025
概括
在埃塞俄比亚,心力衰竭与减少喷射率 (HFrEF) 的指导指导医学治疗是不理想的,只有1.3%的患者达到目标药物剂量. 成本和可用性限制了对ARNI和SGLT2抑制剂等新疗法的获取.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 减少喷射分数 (HFrEF) 的心力衰竭管理依赖于指导方针导向医学治疗 (GDMT).
- 评估GDMT的实施对于改善资源有限的环境中患者的治疗结果至关重要.
研究的目的:
- 评估埃塞俄比亚阿塞拉推和教学医院HFrEF患者的GDMT实施情况.
- 确定与达到目标药物剂量相关的临床因素.
主要方法:
- 对156名HFrEF患者进行了一项横截面研究.
- 数据收集涉及结构化访谈和图表审查.
- 使用SPSS版本26进行统计分析.
主要成果:
- 对RASI,β-阻断剂和MRA的处方率很高 (>70%),但只有1.3%的患者实现了所有三种药物的目标剂量.
- 由于成本和可用性问题,没有患者接受ARNI或SGLT2抑制剂.
- 基线心和糖尿病与达到RASI目标剂量有关.
结论:
- 埃塞俄比亚对HFrEF的GDMT实施不足以达到最佳.
- 包括成本和可用性在内的重大障碍阻碍了获得先进疗法的机会.
- 需要政策干预和结构化定位协议来优化HFrEF管理.
相关概念视频
Heart Failure V: Medical Management
218
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
218
Heart Failure VI: Adjunct Therapies
255
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
255
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
932
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
932
Heart Failure IV: Classification and Diagnostic Evaluation
319
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
319
Rheumatic Heart Disease III: Medical Management
285
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
285
Heart Failure VII: Nursing Interventions
416
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
416


